Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 45   

Articles published

ARNA 2.71
price chart
Buy Arena Before European Approval Comes Through
Arena Pharmaceutical (NASDAQ:ARNA), a company operating in the healthcare sector, is involved in developing and commercializing drugs that target 'G-protein coupled receptors'.
Arena Buyout Rumors Are Overblown
What happens when a small pharmaceutical company hitches its wagon to a drug that finally gains FDA approval? The stock runs, and images of dollars raining down upon the smart early investors cloud reality.
A Valuation Model For Arena's Belviq
With Arena Pharmaceuticals' (ARNA) Belviq finally approved, Arena will be transitioning from being a cash-starved biotech into an earnings-generating one.
The Potential Market For Arena's Belviq
When investors look at an equity they are looking for the potential that the investment made will grow over time because the product the company we invest in has real potential. There is a substantial difference between potential market and the real ...
What Slims Down Fastest After Diet Drugs Are Approved by he FDA? Two Stocks ...  YCharts
Short Interest in Biotech Firms on the Rise
Short interest data has been released from the August 15 settlement date. Overall short sellers have continued to bet on biotech firms compared to the July 31 settlement date.
Arena: Was This Pharmaceutical Stock a Pump and Dump?
These companies cannot be judged on their balance sheet because future earnings depend on FDA approval and successful sales and marketing.
5 Bio-Pharma Stocks To Buy Right Here
Biotechnology and drug stocks offer some of the best potential for big gains in the market. The flip side of that proverbial coin, of course, is a great deal of risk.
Simple Math Showing Why Synergy Pharmaceuticals Is Undervalued
Buying SGYP today after IRWD approval still makes sense just above $5/share. Retail investors have been pounded when trying to play bank-shots off of competitor FDA approvals in recent months.
Earnings Preview: Orexigen Therapeutics
On June 27, 2012, Arena Pharmaceuticals, Inc. and Eisai Inc. announced that the U.S. Food and Drug Administration has approved BELVIQ (pronounced BEL-VEEK) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight ...
People Moves: September 2012
In his new position, he will be working on products in the cardiovascular arena and reports to Kaye Kilgore, associate creative director.